70 results about "Inflammatory infiltration" patented technology

The invention relates to a pharmaceutical composition for treating Hashimoto's thyroiditis and a preparation method thereof. The pharmaceutical composition is composed of bupleurum, radix curcumae, prunella vulgaris, rhizoma Dioscoreae Nipponicae, thunberg fritillary bulb, radix scrophulariae, edible tulip, astragalus, dark plum and other components, and can be made into granules, capsules, tablets or pills by the conventional pharmaceutical processes. The pharmaceutical composition has the effects of soothing liver-qi stagnation, reducing phlegm, removing stasis, and softening hardness to dissipate stagnation, and applies to patients with Hashimoto's thyroiditis and thyroid nodules. Clinical studies have shown that the pharmaceutical composition can significantly improve the symptoms of Hashimoto's thyroiditis, reduce the thyroid volume and isthmus thickness, and reduce the level of TgAb and TPOAb, and the total effective rate is 97.22%. In addition, for patients with thyroid nodules, nodules can be significantly reduced or even disappeare, no significant adverse reactions are presented in the course of treatment. Experimental studies have shown that the pharmaceutical composition reduces the level of TgAb and TPOAb, and reduces inflammatory infiltration and thyroid follicular damage.

The invention discloses an in vitro construction method of liver organs and applications. Mouse hepatocytes are extracted to induce to construct liver organs; the forms of the liver organs are observed under a microscope; and immunofluorescence and PCR identification are performed on dryness and epithelial cell properties. An acute hepatic failure mouse model after 70% hepatectomy is established;the liver functions on the first, fourth and seventh day after operation are evaluated after the liver organs are transplanted; liver-to-body ratio is compared; and the treatment effects of the liverorgans on acute hepatic failure are verified through HE staining and immunohistochemistry. Inflammations such as HE staining and ki-67 staining and proliferation indexes show that proliferation can beobviously enhanced after the liver organs are transplanted. The liver organs have strong dryness and proliferation functions; the liver functions of acute hepatic failure mice after 70% hepatectomy can be effectively relieved, and the liver-to-body ratio can be increased; and liver regeneration and repair of acute hepatic failure after 70% hepatectomy can be promoted by relieving inflammatory infiltration of livers.

The invention relates to a medicine for treating rheumatoid arthritis, wherein the effective component is muscone, and the effective concentration is 10-1000 [mu]M. Muscone is mixed with pharmaceutically acceptable pharmaceutical adjuvants to form powders, ointments, powders, injections, aqueous solutions, enteric-coated sustained-release preparations or injections. As proved by animal experiments, that muscone can reduce joint injury and inflammatory infiltration area, bone mass defect and cartilage defect of the collagen-induced rheumatoid arthritis mice, and alleviate ankle arthritis injury. The muscone of the invention can improve the symptoms of rheumatoid arthritis. The invention also discloses the use of muscone in preparing medicines or health products for preventing and treating rheumatoid arthritis. The effective concentration of muscone is 10-1000 [mu]M.

The invention discloses a compound preparation for treating cecal granuloma and a preparation method thereof. The compound preparation comprises chloroquine phosphate, diiodohydroxyquinoline, chlorogenic acid, liquiritin, cistanoside, ursolic acid, polysavone, levamisole, albendazole, okra powder, lactein, vitamin B1, lactalbumin and arginine. The compound preparation can effectively expand intestinal tubes, prevent intestinal obstruction, prevent mesentery and intestinal wall inflammatory infiltration and edema, prevent intestinal wall fibrosis, adjust body metabolism, improve immunity, reduce drug side effects and treat cecal granuloma and has a wide application prospect.

The invention relates to a medicine for treating rheumatoid arthritis, wherein the effective component is osthole, and the effective concentration is 1-100 [mu]M. Osthole is mixed with pharmaceutically acceptable pharmaceutical adjuvants to form powders, ointments, powders, injections, aqueous solutions, enteric-coated sustained-release preparations or injections. As prove by animal experiments, osthole can reduce joint injury and inflammatory infiltration area of collagen-induced rheumatoid arthritis mice, reduce bone mas defect, alleviate ankle arthritis injury, and improve rheumatoid arthritis symptoms. The invention also discloses the use of osthole in preparing medicine or health product for preventing and treating rheumatoid arthritis.

The invention relates to a medicinal composition for treating alcoholic liver injury. The medicinal composition contains Japanese ginseng total saponins and Japanese ginseng polysaccharides serving as active ingredients and a pharmaceutically acceptable carrier. Due to the adoption of a Japanese ginseng total saponin-polysaccharide composition, certain phenomena can be overcome remarkably, the liver function indexes can be lowered very remarkably, MDA (Methylene Dioxyamphetamine) in liver tissues is reduced, SOD (Superoxide Dismutase) and GSH-Px activity are enhanced, and the inflammatory infiltration and fat vacuoles of liver tissues are reduced.

The invention discloses application of dipyridamole or pharmaceutically acceptable salt thereof in preparation of a medicine for preventing and / or treating lung inflammation. The dipyridamole can inhibit the conversion of fibroblasts into myofibroblasts; meanwhile, the dipyridamole can also improve the respiratory function of a bleomycin-induced pulmonary fibrosis model rat, reduce the inflammatory infiltration of lung tissues and reduce the pathological states such as fibroblast proliferation and collagen accumulation in the lung tissues; and the dipyridamole has relatively high bonding strength with a 3CL enzyme as a pneumonia target triggered by a novel coronavirus in 2019 years, and has relatively high inhibitory activity on the 3CL enzyme of the coronavirus and a Vero E6 cell infected by the coronavirus, indicating that the dipyridamole has the effects of preventing and treating pulmonary fibrosis and pneumonia triggered by the novel coronavirus in 2019 years, and can be preparedinto a pneumonia medicine for application.

The invention discloses a ginsenoside composition with a function of preventing and treating alcoholic fatty liver. The pharmaceutical composition for preventing and / or treating alcoholic fatty liveraccording to the present invention comprises ginsenoside Rk3 and ginsenoside Rh4 as active ingredients in an amount effective to prevent and / or treatment, and a pharmaceutically acceptable carrier, wherein the weight ratio of the ginsenoside Rk3 to the ginsenoside Rh4 is 1: (0.5-2), preferably 1: (0.9-1.1). The ginsenoside composition disclosed by the invention can obviously improve abnormal liverfunction index caused by drinking a large amount of wine; the inflammatory infiltration of liver tissues and the generation of fat vacuoles are reduced. The invention provides a pharmaceutical composition which contains ginsenosides Rk3 and Rh4, has synergistic interaction and has the effect of preventing and / or treating alcoholic fatty liver.

The invention relates to application of an ALDH3A1 / IL-17 axis in preparation of a medicine for treating refractory ulcer. According to the invention, proteomics is combined with biological information analysis, and experimental verification is combined for use, so the protein expression of ALDH3A1 in a wound surface of a db / db diabetic mouse is reduced; and by overexpressing ALDH3A1 expression in HaCaT cells, proliferation of the cells is increased, inflammatory infiltration is relieved, and an IL-17 pathway is remarkably inhibited. It is prompted in the invention that ALDH3A1 can improve chronic inflammation, promote cell proliferation and heal wounds by inhibiting downstream IL-17 signal channels, and the targeted ALDH3A1 / IL-17 axis can be used as a novel treatment method and is used for treating refractory ulcers, chronic inflammation after injury, infection and other types of wounds in the future.

The present invention relates to new uses of an Ajuga ciliata Bunge extract, particularly to applications of the Ajuga ciliata Bunge extract in preparation of drugs for prevention and treatment of gynecological inflammatory diseases. According to the present invention, experimental results show that the gynecological inflammation treatment effects of the Ajuga ciliata Bunge extract on the two chronic pelvic inflammatory disease rat models caused by escherichia coli and phenol paste are verified, wherein the change of the blood rheology, the inflammatory factors and other indicators of the chronic pelvic inflammatory disease rat model caused by the phenol paste are observed after using the Ajuga ciliata Bunge extract, the change of the immunology indicator of the chronic pelvic inflammatory disease rat model caused by the escherichia coli is observed after using the Ajuga ciliata Bunge extract, and the intervention effects of the Ajuga ciliata Bunge extract on the uterus tissue inflammatory infiltration caused by chronic inflammations, tissue adhesion, and inflammatory mass caused by attachment hyperblastosis and the like are observed, such that the Ajuga ciliata Bunge extract provides the treatment effects on the long-term chronic inflammations and the attachment hyperblastosis caused by the long-term chronic inflammations.

The invention discloses application of a fructus schisandrae sphenantherae extract in preparation of a liver regeneration medicine. The fructus schisandrae sphenantherae extract is an alcohol extract of dried fruits of schisandrae sphenantherae, and the main effective ingredients of the fructus schisandrae sphenantherae extract comprise schisantherin and deoxyschizandrin. A partial hepatectomy mouse model is utilized, the fructus schisandrae sphenantherae extract is cooperatively applied, a result shows that the fructus schisandrae sphenantherae extract has the characteristics of being capable of significantly improving the quick recovering capacity of the liver-weight ratio and improving the quick proliferation capacity of liver cells, the mechanism relates to significant activation of protein expression of a related cell cycle, the manifestation is that cyclin D1 and PCNA proteins are significantly up-regulated, and meanwhile obvious improvement on liver tissue inflammatory infiltration and liver cell swelling is achieved. Experimental results show that the fructus schisandrae sphenantherae extract supplies a novel method and treatment means to liver regeneration after hepatectomy.

The invention relates to an extraction technology of pongamia pinnata extract and a use of the pongamia pinnata extract in treatment on the liver injury. The extraction technology is effectively used for researching a drug for treating the liver injury. Pongamia pinnata has a high medicinal value and root, leaves, fruits and seeds of pongamia pinnata have medicinal effects. Through the ages, in a civil field, pongamia pinnata is used for treating acute and chronic viral hepatitis and jaundice and has good effects. An effective ingredient is a Gea-Yea mixture separated from pongamia pinnata. The Gea and Yea extract can obviously improve a survival rate of a mice having a D-GalN / LPS-induced acute liver injury, can reduce liver coefficients of a mice having obstructive jaundice, can reduce ALT, AST, LDH and TBIL levels of serum, can reduce MDA and NO content of liver tissue, can relieve pathological symptoms such as necrosis, degeneration and inflammatory infiltration of liver tissue and has obvious prevention and control effects. The extraction technology is simple, economic and practical. The Gea-Yea mixture has obvious effects of improving all indexes of the liver injury, has good treatment effects and has a good application prospect.

The invention relates to a method and a system for analyzing an eye picture and attribute information. The method comprises the following steps: acquiring the eye picture of a user suffering from keratitis and the attribute information of the user; judging classification information of the eye picture according to the inflammatory infiltration and / or ulcer shape of the eye picture; and according to the attribute information and the classification information, obtaining the probability that the keratitis suffered by the user belongs to different categories. A professional ophthalmologist is notneeded. The probability of the keratitis type of the user can be obtained only by uploading the eye picture and the attribute information, reliable reference data are provided for the user or doctorsto make diagnosis and treatment decisions, the method can be popularized to primary hospitals, more primary crowds are popularized, the defect that existing medical resources are not evenly distributed is overcome, and burdens of professional ophthalmologists are relieved.

The invention discloses a triptolide autolytic microneedle. A prescription of a needle tip matrix of the triptolide autolytic microneedle comprises the following components of, in parts by weight, 24-29 parts of PVP (Polyvinyl Pyrrolidone), 7.8-8.3 parts of PVA (Polyvinyl Alcohol), 0.45-0.65 part of CMC-Na (Sodium Carboxymethyl Cellulose), 0.28-0.42 part of triptolide, 40-45 parts of distilled water and 20-23 parts of absolute ethyl alcohol; and a prescription of a backing layer matrix of the triptolide autolytic microneedle comprises the following components of, in parts by weight, 32-37 parts of PVP (Polyvinyl Pyrrolidone), 9-12 parts of PVA (Polyvinyl Alcohol) and 53-58 parts of distilled water. The microneedle has good microneedle formability and mechanical strength, an RSD value of a medicine loading capacity is 0.98%, a process is stable and feasible, a needle tip of a medicine-loading microneedle enables most of medicines to rapidly reach a body to take effect rapidly, and the medicine use safety of the triptolide can be improved due to a slow-release effect of a microneedle matrix; and by reducing inflammatory infiltration of cells in a synovial membrane, the expression of inflammatory factors such as TNF-alpha, IL-17, PGE2, IgG, IgM and IgA can be reduced, the expression of OPG can be increased, the expression of RANKL and an RANKL / OPG ratio can be reduced, and rheumatoid arthritis can be treated.

The invention relates to application of an eIF3I-PDL1-IRS4 axis in preparation of a medicine for treating refractory ulcer. It is found that: when PDL1 is used for treating wounds, tissue formation, inflammation fading and reduction in vascularity can be induced; epithelization is accelerated; inflammation is relieved; healing of diabetic ulcer (DU) wounds is helped; in a DU wound surface, the expression of IRS4 is increased; the expression of the IRS4 of HaCaT cells is knocked down; the proliferation and migration of the cells are increased; when the eIF3I is over-expressed in HaCaT cells, the proliferation and migration of the cells are remarkably increased; and inflammatory infiltration is relieved. The invention prompts that the targeted eIF3I-PDL1-IRS4 axis can be used as a novel treatment method for treating refractory ulcer, chronic inflammation after injury, infection and other types of wounds.

The invention belongs to the field of medicines and provides a medicine for treating non-alcoholic steatohepatitis (NASH). A compound kinsenoside (3-(R)-3-beta-D-glucopyranosyloxbutanolide has a good treatment effect on NASH of mice induced by using an MCD feed (methionine-choline-deficient feed), can effectively reduce liver fat accumulation, relieve liver injury, reduce inflammatory infiltration and oxidative stress injury, and reduce expression of fibrosis marker gene and protein so as to prevent NASH from developing to hepatic fibrosis, indicating that the kinsenoside can be used as a medicine for treating NASH.

The invention relates to applications of the total cyclopentene iridoid glycoside of Hedyotis diffusa Willd in preparation of acute kidney injury prevention and treatment drugs. According to the present invention, in the applications, with the drugs, the inflammatory infiltration of renal tissue can be significantly reduced, the amount of TNF-alpha, IL-1beta, IL-6 and MCP-1 can be effectively inhibited, and the kidney injury prevention and treatment effects are remarkable.

The invention relates to the application of staphylococcal nuclease (SNase) in preparation of a medicament for preventing or treating inflammatory bowel disease. The object of the present invention isto provide a novel use of SNase in action of resisting inflammatory bowel disease. Results show that SNase can significantly alleviate colonic inflammation in C57BL / 6J mice, can better control the body weight, colon length, fecal occult blood and inflammatory infiltration of the C57BL / 6J mice, and significantly improve the survival rate of the C57BL / 6J mice. Therefore, the SNase can significantlyalleviate intestinal inflammation in the C57BL / 6J mice, and can be used for development of medicaments for prevention and treatment of inflammatory bowel diseases.

The invention belongs to the technical field of medicines for treating asthma, and particularly relates to application of polygonatum odoratum polysaccharide in preparation of medicines for treating asthma. Experimental research finds that the polygonatum odoratum polysaccharide can improve release of allergic asthma related cell factors in an airway, reduce the number of eosinophilic granulocytes, reduce serum total IgE, improve allergy conditions and improve pathological conditions such as lung inflammatory infiltration, goblet cell metaplasia and pulmonary parenchyma of asthma mice. Therefore, the polygonatum odoratum polysaccharide can be used for preparing the medicine for treating asthma.

The invention relates to a compound preparation for treating rheumatoid arthritis. The compound preparation is prepared from the following crude drugs in parts by weight: 5 to 12 parts of fried fructus arctii, 4 to 11 parts of bombyx batryticatus, 8 to 15 parts of radix notoginseng, 4 to 12 parts of radix angelicae pubescentis, 3 to 9 parts of radix gentianae macrophyllae, and 4 to 12 parts of rhizoma pinelliae. The animal experiment shows that the compound preparation can reduce an inflammatory infiltration area, bony defects and articular cartilage defects of TNF-Tg rheumatoid arthritis mice, can promote lymphatic return and can alleviate ankle joint inflammatory injury. The traditional Chinese medicine compound preparation can improve the rheumatoid arthritis symptom, and can avoid the inconvenience caused by the temporary decoction of the traditional Chinese herbal decoction before the administration and the likeliness in mildew; and in addition, the invention also provides a preparation method of the compound preparation.

The invention relates to novel application of Metrnl, belongs to the technical field of medicine and in particular relates to application of the Metrnl in atherosclerosis (AS) resistance. A Metrnl<- / ->ApoE<- / -> double-knockout mouse AS model and an EC-Metrnl<- / ->ApoE<- / -> mouse AS model are constructed, experiments show that the severity of AS of the two Metrnl knockout mice is higher than that ofcontrol mice, reflected in that aortas of the Metrnl knockout mice havemore atherosclerotic plaques than those of control mice, the area ratio of the atherosclerotic plaques of the aortas of the Metrnl knockout mice is higher than that of control mice, the thickening degree and inflammatory infiltration degree of root atherosclerosis of the aortas of the Metrnl knockout mice are higher than thoseof control mice and the expression level of inflammatory factors of the aortas of the Metrnl knockout mice is increased. The invention proves that the Metrnl can be applied to AS resistance by experimentsfor the first time.

The invention provides a sunflower disc extract, a medicine containing the sunflower disc extract as well as a preparation method and application of the medicine, and belongs to the technical field of biological medicines. The preparation method of the sunflower disc extract comprises the following steps: mixing crushed sunflower discs with water, carrying out extracting, adding cellulase into the obtained water extract, carrying out hydrolyzing to obtain hydrolysate, carrying out solid-liquid separation on the hydrolysate, and collecting liquid components to obtain the sunflower disc extract. The sunflower disc extract prepared by the invention can significantly inhibit the increase of MDA content, liver index, ALT and AST activity caused by alcohol acute liver injury, effectively inhibit the reduction of SOD activity in the liver, and reduce the liver tissue injury degree of mice, and HE staining shows that the sunflower disc extract can alleviate the inflammatory infiltration phenomenon of liver cells. The sunflower disc extract has an obvious repairing effect on alcohol-induced acute liver injury of mice.

The invention discloses a Chinese herbal medicine composition with effects of diminishing inflammation and relieving itching. The Chinese herbal medicine composition comprises the following components in parts by mass: 55-65 parts of fructus cnidii, 15-25 parts of realgar, 25-35 parts of rheum officinale, 10-20 parts of borneol, 1-2 parts of dragon's blood, 10-20 parts of red flower, 10-20 parts of Red Paeony Root, 5-15 parts of Ligusticum wallichii, 25-35 parts of pawpaw, 5-15 parts of Angelica sinensis, 5-15 parts of Coptis chinensis, 5-15 parts of cortex moutan, 10-20 parts of the seed of cowherb, 10-20 parts of selfheal and 15-25 parts of honeysuckle. The invention also discloses a method for preparing the Chinese herbal medicine composition with effects of diminishing inflammation and relieving itching. The Chinese herbal medicine composition disclosed by the invention has the effects of killing parasites to relieve itching, inducing diuresis to remove turbidity, clearing away heat and toxic materials, promoting blood circulation and expelling wind, inhibiting release of inflammatory factors and alleviating inflammatory infiltration, and good effects of diminishing inflammation and relieving itching are achieved.

The invention discloses an application of total flavonoids of rosa roxburghii in preparation of drugs, health-care products and health-care food for preventing and treating alcoholic liver disease. Provided are drugs and health-care products for preventing and treating alcoholic liver disease, wherein the drugs and health-care products comprise 3-99% of the total flavonoids extract of rosa roxburghii, and the total flavonoids extract of rosa roxburghii are used as an active ingredient. The invention also provides health-care drinks suitable for patients with alcoholic liver disease, wherein the health-care drinks comprise 0.08-1% of the total flavonoids of rosa roxburghii. Through implementation of a most recognized model of alcoholic liver disease in mice, the total flavonoids of rosa roxburghii are found out to obviously alleviate the liver pathological changes induced by alcohol; liver enlargement, weight gain, fat accumulation and inflammatory infiltration degree are significantlyimproved; biochemical and pathological indicators are decreased greatly. Therefore, the total flavonoids of rosa roxburghii can prevent and treat alcoholic liver disease, can be used as drugs separately or in combination and are used for developing corresponding drugs, health-care products or health-care food.

The invention discloses an application of various rosa roxburghii aqueous extracts in preparation of drugs, health-care products and health-care food for preventing and / or treating alcoholic liver disease. Provided are drugs and health-care products for preventing and treating alcoholic liver disease, wherein the drugs and health-care products comprise 20-99% of the rosa roxburghii aqueous extracts. The invention also provides health-care drinks suitable for patients with alcoholic liver disease, wherein the health-care drinks comprise 0.5-33% of the rosa roxburghii aqueous extracts; the invention also provides a blended alcoholic drinks comprising 0.5-7% of the rosa roxburghii aqueous extracts; the invention also provides fruit-flavored beer drinks comprising 0.5-4% of the rosa roxburghiiaqueous extracts; the invention also provides additive grape wine comprising 0.5-2% of the rosa roxburghii aqueous extracts; the invention also provides blended grape wine drinks comprising 0.5-2% ofthe rosa roxburghii aqueous extracts. Through implementation of the most recognized model of alcoholic liver disease in mice, the rosa roxburghii aqueous extracts with various concentrations are found out to alleviate the liver pathological changes induced by alcohol in different extents; liver enlargement, weight gain, fat accumulation and inflammatory infiltration degree are significantly improved; biochemical and pathological indicators are significantly reduced. The rosa roxburghii aqueous extracts can prevent and treat alcoholic liver disease, can be used as drugs separately or in combination, and is used for developing corresponding drugs, health-care products or health-care food.

The invention discloses a novel nano sustained-release drug-loaded material for inhibiting antibody-mediated rejection reaction in a targeted immune hair growth center, a preparation method and application. The novel nano drug-loaded material has targeting property, can slowly release drugs, can be used for treating inflammatory infiltration of transplanted organs, and is low in toxicity (low in neurotoxicity and renal toxicity) and small in side effect.

Chronic obstructive pulmonary disease (COPD) is still the major cause of global morbidity and mortality. A COPD acute exacerbation patient (AE-COPD) is mainly caused by respiratory tract infection and is related to inevitable decline of lung function, edema exacerbation and airway and systemic inflammation. Previous results show that treatment with an anti-IL-20Rb blocking antibody increases bacterial clearance in control mice infected with Streptococcus pneumoniae and protects CS exposed mice from bacterial infection by reducing bacterial load and inflammatory infiltration. Therefore, people are of interest in the production of monoclonal antibodies specific for IL-20Rb with neutralizing activity for AE-COPD treatment. This need is met by providing an antibody that is specific for IL-20Rb.

The invention relates to a composition for repairing epithelial injury of bladders and urinary tracts. The composition is composed of two or three components selected from a group including hyaluronic acid, chitosan and chondroitin sulphate. Clinical animal experiments show that the composition for repairing epithelial injury of bladders and urinary tracts disclosed by the invention is capable of obviously repairing epithelial injury of bladders due to protamine sulphate or cyclophosphamide, obviously reducing the bladder epithelial injury range and the injury degree and lightening the inflammatory infiltration degree.

The invention discloses application of glutathione (GSH) to preparation of a drug for preventing and treating central nervous system infection caused by salmonella typhimurium. A mouse meningitis model with the single-side ventricle being injected with the salmonella typhimurium SL1344 is provided, it is proven that the GSH has good treating activity, an experiment proves that the GSH can significantly prolong the median survival time of mice, the meningitis EAE score is increased, brain edema and inflammatory infiltration are relieved, and in addition, the GSH can relieve brain cell apoptosisby lowering phosphorylation of JNK.